Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2014; 20(29): 10174-10182
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10174
Clinical outcome of small hepatocellular carcinoma after different treatments: A meta-analysis
Wei Dong, Ting Zhang, Zhen-Guang Wang, Hui Liu
Wei Dong, Ting Zhang, Zhen-Guang Wang, Hui Liu, the Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
Author contributions: Liu H designed the research and provided financial support for this study; Dong W and Zhang T performed the literature search; Wang ZG collected the clinical data from the literature and analyzed these data; Dong W wrote the manuscript.
Supported by National Key Basic Research Program of China - 973 Program, No. 2012CB526706; International Science and Technology Cooperation Program of the Ministry of Science and Technology, No. 2011DFA32980; The Innovation Program of Shanghai Municipal Education Commission, No. 2013ZZ060; and the National Natural Science Foundation of China, No. NSFC81271694
Correspondence to: Hui Liu, Associate Professor, the Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, NO.225, Changhai Road, Yangpu district, Shanghai 200438, China. happyehbh@163.com
Telephone: +86-21-65389998 Fax: +86-21-65562400
Received: January 4, 2014
Revised: February 26, 2014
Accepted: March 19, 2014
Published online: August 7, 2014
Abstract

AIM: To compare clinical outcomes between surgical resection (RES) and nonsurgical-RES (nRES) ablation therapies for small hepatocellular carcinoma (HCC).

METHODS: MEDLINE, Embase and Cochrane Library databases were systematically searched for studies of RES and nRES treatments for small HCC between January 2003 and October 2013. The clinical outcome measures evaluated included overall survival rate, disease-free survival rate, adverse events, and local recurrence rate. Odds ratios (ORs) with 95%CIs were calculated using either the fixed effects model or random effects model. The χ2 and I2 tests were calculated to assess the heterogeneity of the data. Funnel plots were used to assess the risk of publication bias.

RESULTS: Our analysis included 12 studies that consisted of a total of 1952 patients (RES vs nRES), five studies that consisted of 701 patients [radiofrequency ablation (RFA) vs percutaneous ethanol injection (PEI)], and five additional studies [RFA vs RFA + transcatheter arterial chemoembolization (TACE)] that all addressed the treatment of small HCC. For cases of RES vs nRES, there was no significant difference in the 1-year (OR = 0.99, 95%CI: 0.87-1.12, P = 0.85) or 3-year (OR = 0.97, 95%CI: 0.84-1.11, P = 0.98) overall survival rate; however, there was a significant increase in the RES group in the 5-year overall survival rate (OR = 0.81, 95%CI: 0.68-0.95, P = 0.01). The 1-year (OR = 0.94, 95%CI: 0.82-1.08, P = 0.37) and 5-year (OR = 0.99, 95%CI: 0.85-1.14, P = 0.85) disease-free survival rates showed no significant differences between the two groups. The 3-year disease-free survival rate (OR = 0.81, 95%CI: 0.69-0.96; P = 0.02) was higher in the RES group. For cases of RFA vs PEI, our data analysis indicated that RFA treatment was associated with significantly higher 2-year (OR = 0.76, 95%CI: 0.58-0.99, P = 0.043) and 3-year (OR = 0.73, 95%CI: 0.54-0.98, P = 0.039) overall survival rates; however, there were no significant differences in the 1-year (OR = 0.92, 95%CI: 0.72-1.17, P = 0.0502) overall survival rate or incidence of adverse events (OR = 1.84, 95%CI: 0.76-4.45, P = 0.173). For cases of RFA vs RFA+TACE, there were no significant differences in the 1-year (OR = 1.17, 95%CI: 0.88-1.56, P = 0.27) or 3-year (OR = 1.25, 95%CI: 0.90-1.73, P = 0.183) overall survival rate; however, the 5-year overall survival rate (OR = 3.19, 95%CI: 1.51-6.74, P = 0.002) in patients treated by RFA+TACE was higher than that treated by RFA alone.

CONCLUSION: Surgical resection is superior to nonsurgical ablation for the treatment of small HCC. Among the studies analyzed, RFA is the most efficacious single nonsurgical ablation treatment.

Keywords: Hepatocellular carcinoma, Meta-analysis, Surgical resection, Nonsurgical ablation, Radiofrequency ablation, Percutaneous ethanol injection, Recurrence, Survival

Core tip: The efficacy of surgical resection over nonsurgical ablation for the treatment of small hepatocellular carcinoma has long been debated. In previous studies, a meta-analysis was conducted on cases of resection (RES) vs radiofrequency ablation or RES vs other single nonsurgical ablation methods. Our meta-analysis was designed to determine the superior choice of treatment for small hepatocellular carcinoma from among surgical resection and nonsurgical ablation methods.